KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth Sells 4,163 Shares

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 4,163 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total value of $19,774.25. Following the sale, the chief financial officer now directly owns 60,187 shares of the company’s stock, valued at $285,888.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Mary Reumuth also recently made the following trade(s):

• On Friday, May 31st, Mary Reumuth sold 1,786 shares of KALA BIO stock. The stock was sold at an average price of $6.09, for a total value of $10,876.74.

KALA BIO Trading Up 40.2 %

NASDAQ KALA traded up $1.85 during trading on Thursday, hitting $6.45. The stock had a trading volume of 11,577,913 shares, compared to its average volume of 118,861. The company has a market capitalization of $18.19 million, a PE ratio of -0.43 and a beta of -1.97. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 4.92. The firm has a 50 day moving average price of $6.38 and a 200 day moving average price of $7.02. KALA BIO, Inc. has a twelve month low of $4.21 and a twelve month high of $16.11.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, May 14th. The company reported ($4.20) earnings per share for the quarter, missing the consensus estimate of ($2.89) by ($1.31). As a group, equities research analysts forecast that KALA BIO, Inc. will post -14.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Monday, April 1st. HC Wainwright cut their price objective on KALA BIO from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, May 17th.

Hedge Funds Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Tower Research Capital LLC TRC bought a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned approximately 0.16% of KALA BIO at the end of the most recent reporting period. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.